Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-1.92%||6.14||0.7%||$429.21m|
|REGN||Regeneron Pharmaceuticals, Inc.||1.59%||552.11||2.7%||$426.22m|
|GILD||Gilead Sciences, Inc.||1.52%||66.90||1.0%||$414.02m|
|XLRN||Acceleron Pharma, Inc.||0.43%||173.74||5.3%||$364.00m|
|VRTX||Vertex Pharmaceuticals, Inc.||2.55%||185.41||1.9%||$264.85m|
|XENE||Xenon Pharmaceuticals, Inc.||-2.96%||29.81||0.4%||$166.66m|
|DNA||Ginkgo Bioworks Holdings, Inc.||20.21%||14.81||0.0%||$162.54m|
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.